Russia to Jointly Produce Sputnik V COVID-19 Vaccine With India

This announcement comes at a time when the India has announced that vaccination drive is likely to start in January.

1 min read
Currently Sputnik V Phase III clinical trials are approved and are underway in Belarus, the UAE, Venezuela and other countries, as well as Phase II-III in India.

The Russian envoy to India Nikolay Kudashev announced on Monday, 21 December, that Moscow and New Delhi will jointly produce that Sputnik V vaccine against COVID-19 in collaboration with Dr Reddy's Laboratories.

"We are working very hard to fight COVID-19 together with India, and are now advancing to jointly produce Sputnik V vaccine at the capacities of Dr Reddy's Laboratories to be used in India, Russia and other countries," Kudashev said, addressing a press conference, reported news agency PTI.

On 11 August, the Sputnik V vaccine developed by the Gamaleya National Research Institute of Epidemiology and Microbiology was registered by the Ministry of Health of Russia and became the world's first registered vaccine against COVID-19 based on the human adenoviral vector platform.

“We have supported each other in a big way earlier this year when we managed to repatriate thousands of Russian and Indian nationals to their respective home countries,” he said.

This announcement comes at a time when the Union Health Ministry has announced that vaccination drive is likely to start from January.

Sputnik V vaccine has reportedly shown 92 percent efficacy in preventing COVID-19, according results announced by the country’s health ministry.

In September 2020, Dr Reddys and Russian Direct Investment Fund (RDIF) into a partnership to conduct clinical trials of Sputnik V vaccine and its distribution in India. RDIF is expected to supply 100 million doses of the vaccine to the pharma giant upon regulatory approval in India.

(With inputs from PTI)

(The Quint is available on Telegram. For handpicked stories every day, subscribe to us on Telegram)

Stay Updated

Subscribe To Our Daily Newsletter And Get News Delivered Straight To Your Inbox.

Join over 120,000 subscribers!